论文部分内容阅读
1.丙戊酸钠——胎儿畸形风险:日前澳大利亚(WHO Pharmaceuticals Newsletter.2009,No.3)针对丙戊酸钠潜在的致畸胎风险,已提醒医务人员在为育龄妇女因任一适应证应用丙戊酸钠时,应告知患者该药的可能风险中包括畸胎;并着重建议医务人员应定期提醒她们在用药期间采取适当的避孕措施。丙戊酸钠是可致胎儿畸形的药物,畸胎发生的风险呈现剂量相关性,若在妊娠早期(前3个月)应用剂量>1 100 mg·d~(-1)时风险显著增加。
1. Sodium valproate - risk of fetal malformations: The recent risk of teratogenicity in sodium valproate in Australia (WHO Pharmaceuticals Newsletter 2009, No. 3) has reminded medical staff that, for any indications of childbearing age, When applying sodium valproate, the patient should be informed of the possible risks of the drug, including teratology, and it is strongly suggested that medical staff should be regularly reminded of appropriate contraceptive use during the medication. Sodium valproate is a drug that can cause fetal malformations. The risk of teratogenicity is dose-related. If the dose is more than 1,100 mg · d -1 during the first trimester of pregnancy, the risk is significantly increased.